DCOY Projected Dividend Yield
Decoy Therapeutics Inc ( NASDAQ : DCOY )Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Co.'s lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. 22 YEAR PERFORMANCE RESULTS |
|
DCOY Dividend History Detail DCOY Dividend News DCOY Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |


